

Australian Clinical Labs Limited

ABN 94 645 711 128 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia

clinicallabs.com.au

Monday, 23 October 2023

2023 ANNUAL GENERAL MEETING RESULTS

In accordance with Listing Rule 3.13.2 and section 251AA of the *Corporations Act* 2001, Australian Clinical Labs Limited (ASX:ACL)(**Company**) announces the outcome of each resolution put to shareholders at its Annual General Meeting, which was held today.

The following resolutions were passed on a poll, with full details of the number of votes and the total number of proxy votes appearing at Appendix A to this announcement:

- 1. Adoption of 2023 Remuneration Report
- 2. Re-election of Ms Christine Bartlett
- Re-election of Mr Mark Haberlin
- 4. Re-election of Dr Leanne Rowe AM
- 5. Approval of the grant of performance rights to Ms Melinda McGrath
- 6. Renewal of the Proportional Takeover Provisions

Shareholders who were unable to attend the AGM will find a recording of the Chair's and CEO's address on the Company's <u>website</u>.

- ENDS -

This announcement was authorised for release to ASX by the Company Secretary of ACL.

For further information regarding this announcement, please contact:

Governance

Eleanor Padman Company Secretary

Email: epadman@padmanadvisory.com.au

Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.



AUSTRALIAN CLINICAL LABS LIMITED

RESULT OF ANNUAL GENERAL MEETING (ASX REPORT)

ANNUAL GENERAL MEETING Monday, 23 October, 2023

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (open votes)	Abstain	For	Against	Abstain **	Result
1	ADOPTION OF THE REMUNERATION REPORT	N	144,093,230 98.05%	1,949,119 1.33%	923,549 0.63%	157,219	145,018,779 98.67%	1,949,119 1.33%	160,219	Carried
2	RE-ELECTION OF MS CHRISTINE BARTLETT AS A DIRECTOR	NA	144,824,717 98.43%	1,396,288 0.95%	908,650 0.62%	40,962	145,738,367 99.05%	1,396,288 0.95%	40,962	Carried
3	RE-ELECTION OF MR MARK HABERLIN AS A DIRECTOR	NA	135,939,683 92.39%	10,281,922 6.99%	908,650 0.62%	40,362	136,853,333 93.01%	10,281,922 6.99%	40,362	Carried
4	RE-ELECTION OF DR LEANNE ROWE AM AS A DIRECTOR	NA	144,877,002 98.47%	1,341,913 0.91%	915,457 0.62%	36,245	145,797,459 99.09%	1,341,913 0.91%	36,245	Carried
5	APPROVAL OF GRANT AND ISSUE OF PERFORMANCE RIGHTS TO MS MELINDA MCGRATH	NA	144,013,720 97.98%	2,053,480 1.40%	922,346 0.63%	133,571	144,941,066 98.60%	2,053,480 1.40%	133,571	Carried
6	RENEWAL OF THE PROPORTIONAL TAKEOVER PROVISIONS IN THE CONSTITUTION	NA	129,223,440 87.89%	16,872,037 11.48%	927,346 0.63%	147,794	130,155,786 88.52%	16,872,037 11.48%	147,794	Carried

^{** -} Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item